● You lead the statistical design of complex or high priority early phase studies, including adaptive, platform, and biomarker enriched trials
● You champion the use of innovative methodologies, for example Bayesian designs and model based dose selection, aligned with exploratory objectives and scientific hypotheses
● You ensure strategic alignment and quality across statistical deliverables within early phase programs, shaping the statistical framework that supports phase transitions, internal governance reviews, and regulatory interactions
● You solve complex statistical challenges in early development using deep expertise and novel approaches, such as integrating translational data, navigating sparse or emerging datasets, and balancing speed with scientific rigor
● You interpret and drive the narrative around emerging data, translating early signals into clear, meaningful insights for internal stakeholders and external communications
● You own the statistical content of major early regulatory submissions, such as INDs, EMA scientific advice packages, and pre IND or end of Phase 1 meetings, ensuring clarity, integrity, and scientific robustness
● You lead sub streams and functional contributions within disease area strategy and the integration of novel data sources, for example omics, imaging, and real world data
● You maintain strong connectivity and collaboration with other core biometrics functions within PDD, including Biostatistics, Analytical Data Science, and Data Management, ensuring early phase analysis strategies are executable